Feasibility Assessment of Cardiovascular Endurance Training for the Symptomatic Improvement of Irritable Bowel Syndrome Patients With a Sedentary and Non-active Lifestyle.

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05680766
Collaborator
(none)
30
1
48

Study Details

Study Description

Brief Summary

This exploratory study's primary objective is the changes of irritable bowel syndrome (IBS) symptom severity by cardiovascular endurance training (CET) in relation to the baseline sedentary or non-active lifestyle. Secondary endpoints focus on the mechanisms associated with these changes.

These mechanisms relate to dietary adaptations, changes in anxiety, depressive comorbidity, somatisation, alterations in the gut microbiome or metabolome, body composition and measures of cardiovascular fitness. Virtually all IBS guidelines mention lifestyle modifications as a management option.

Research on the role of physical activity remains underassessed as compared to the other interventions. Therefore, an exploratory proof-of-concept study will investigate the influence of regular physical exercise on symptoms in a small group of IBS patients. This study will gather data on putative underlying mechanisms related to dietary factors, faecal microbiome and metabolome, mental well-being, body composition and cardiovascular fitness.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiovascular endurance training
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Feasibility Assessment of Cardiovascular Endurance Training for the Symptomatic Improvement of Irritable Bowel Syndrome Patients With a Sedentary and Non-active Lifestyle.
Anticipated Study Start Date :
Jan 2, 2023
Anticipated Primary Completion Date :
Jan 2, 2026
Anticipated Study Completion Date :
Jan 2, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention arm

IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).

Other: Cardiovascular endurance training
Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.

Outcome Measures

Primary Outcome Measures

  1. Change of IBS Symptom severity [from baseline to 12 weeks]

    this will be assessed after patients have done a cardiovascular endurance training

Secondary Outcome Measures

  1. Change of IBS Symptom severity [from baseline to 6 weeks]

    this will be assessed after patients have done a cardiovascular endurance training

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18 - 60 years;

  • Fulfilling the ROME IV criteria for Irritable bowel syndrome (IBS);

  • Moderate symptom severity as defined by a IBS-Symptom Severity Scale > 175;

  • Sedentary lifestyle defined as SIT-Q-7D > 8h/day;

  • Physically inactive defined as < 150min/week on the IPAQ score

Exclusion Criteria:
  • Cardiorespiratory disorder hampering participation in a program of physical exercise as evidenced by the sport + keuringsartsen (SKA) questionnaire.

  • Clinical suspicion of an organic disorder different from IBS (patients can be included when this disorder had been excluded);

  • Known inflammatory bowel disorder;

  • Known intestinal motility disorder;

  • Alcohol (defined as more than 14 U per week) or other substance abuse;

  • Active psychiatric disorder;

  • Known systemic or auto-immune disorder with implication for the GI system;

  • Prior abdominal surgery (with the exception of appendectomy or cholecystectomy more than 6 months ago);

  • Any prior diagnosis of cancer other than basocellular carcinoma;

  • Current chemotherapy;

  • History of gastro-enteritis in the past 8 weeks;

  • Change in diet in the past 8 weeks;

  • Dietary supplements unless taken at a stable dose for more than 8 weeks;

  • Antibiotics, pre-, pro-, post-biotics or any combination during the past 8 weeks;

  • Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed);

  • Treatment with spasmolytic agents, opioids, loperamide, gelatine tannate or mucoprotect-ants during the past 8 weeks.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Universitair Ziekenhuis Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT05680766
Other Study ID Numbers:
  • Face-IT
First Posted:
Jan 11, 2023
Last Update Posted:
Jan 11, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2023